Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population1These authors contribute equally.

Fang, Dong; Xiong, Gengyan; Li, Xuesong; Kang, Yongming; Zhang, Lei; Zhao, Guangzhi; Chen, Xiaopeng; Yao, Lin; Zhang, Xiaoyu; Yu, Wei; Gong, Kan; Song, Yi; He, Qun; He, Zhisong; Zhou, Liqun; Guo, Yinglu

doi:10.1016/j.urolonc.2014.07.001

Cited by 22 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urothelial carcinomas are distinguished by their ability to develop multiple foci in a synchronous or sequential fashion throughout the urinary tract 1 . Upper tract urothelial carcinoma (UTUC) and bladder tumor (BT) often co-exist 2 3 , and 1.6% to 6.9% of UTUC patients have been reported to suffer from synchronous or metachronous bilateral disease 4 5 6 .…”

mentioning

confidence: 99%

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Fang

Liu

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

The incidence of pan-urothelial cell carcinoma (panUCC), which refers to the presence of both bilateral (UTUC) and bladder tumor (BT), is relatively low. However, the profile of a panUCC cohort of patients remains to be elucidated. We reviewed the data of consecutive UTUC patients who received treatment at our center from 1999 to 2012. Overall, 45 patients were included in this study, with a median age of 64.5 years. Fourteen patients initially presented with unilateral UTUC, 11 initially with BT, and the remainder with multiple tumors. Patients with UTUC were more likely to manifest higher rates of muscle invasion and larger-sized tumors. Five patients were treated with complete urinary tract exenteration (CUTE), and most patients (73.3%) received combined management with conservative and radical surgery. After a median follow-up of 77 months, 18 patients (40%) died including 15 (33.3%) due to cancer. Higher tumor stage was the only risk factor predictive of worse survival. Nineteen patients experienced local recurrence after conservative surgery. This study indicated that PanUCC involves either synchronous or metachronous presentation of tumors with a high risk of tumor recurrence, progression, and dissemination after conservative surgery.

show abstract

mentioning

confidence: 99%

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Fang

Liu

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…The disease recurred in 36.8% of the cases, while bladder tumors recurred in 31.6%. The oncological outcomes resemble those of unilateral UTUC, and the median cancer-specific survival rate was 81.2% [6]. In 15 cases of synchronous bilateral tumors published by Holmang and Johansson [8], the use of phenacetin-containing analgesics was an etiological factor in 20% of the cases.…”

Section: Discussionmentioning

confidence: 93%

“…In 17% of the cases, concomitant bladder tumors are present [5]. Synchronous bilateral UTUC is rare and has been reported in 0.8-4.7% of the cases [4,6,7]. Guidelines recommend follow-up and a treatment algorithm for unilateral UTUC; data is available for synchronous bilateral UTUC in only a few retrospective case series.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of Synchronous Bilateral Upper Urinary System Urothelial Carcinoma

Buldu¹,

Kurt²,

Inan³

et al. 2016

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetÜretelyal kanserler insanda 4.en sık görülen tümörler olmasına rağmen senkronize bilateral üst üriner sistem üretelyal kanseri (UTUC) oldukça nadir görülmekte-dir. Yüksek riskli unilateral UTUC olan hastalarda radikal nefroüreterektomi (RNU) gold standart tedavi yöntemidir. Fakat senkronize bilateral UTUC için tedavi yön-temi konusunda bir konsensüs mevcut değildir. Hasta ve tümörün değerlendirme-sine göre karar verilmesi önerilmiştir. Bu vakada 53 yaşında senkronize bilateral yüksek riskli UTUC ile başvuran hastaya bilateral nefron koruyucu yöntem (NSS) uygulanmış ve sonuçları ortaya konulmuştur. Anahtar KelimelerSenkronize; Bilateral Üst Üriner Sistem; Ürotelyal Kanser; Tedavi AbstractSynchronous bilateral upper urinary tract urothelial cancer (UTUC) is a very rare form of urothelial cancer. In patients with high-risk unilateral UTUC, radical nephroureterectomy (RNU) is the gold standard treatment. However, there is no consensus on the treatment for synchronous bilateral UTUC. Evaluation of the patient and the tumor is recommended. Bilateral nephron-sparing surgery (NSS) was performed on a 53-year-old patient who presented with high-risk synchronous bilateral UTUC, and the outcome was reported.

show abstract

“…[ 3 4 5 ] Previous studies have suggested that differences existed in the etiologies, characteristics, predictors, and oncologic outcomes among populations. [ 6 7 8 ] Radical nephroureterectomy (RNU) is the standard treatment for UTUC patients. However, the outcome is far from satisfactory due to the high risk of postoperative systemic recurrence.…”

Section: Introductionmentioning

confidence: 99%

Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma

Cao

Guan

Zhao

et al. 2017

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Background:The pretreatment neutrophil-to-lymphocyte ratio (NLR) has been reported to be a prognostic factor in various types of carcinomas. The aim of this study was to investigate the prognostic value of pretreatment NLR in a large cohort of Chinese patients with upper tract urothelial carcinoma (UTUC).Methods:We retrospectively analyzed the medical data of 656 UTUC patients who underwent radical nephroureterectomy (RNU) from 2001 to 2011 at Peking University First Hospital. Receiver operating characteristic (ROC) curve analysis was performed to calculate the optimal cutoff point of pretreatment NLR. Uni- and multi-variate analyses were used to identify the prognostic factors for cancer-specific survival (CSS) and intravesical recurrence-free survival (IVRFS).Results:The optimal cutoff point of pretreatment NLR was 2.40 by ROC curves, by which patients with high NLR (NLR ≥2.40) and low NLR (NLR <2.40) accounted for 314 (47.9%) and 342 (52.1%) patients, respectively. Patients with a high pretreatment NLR tended to have high tumor grades (χ2 = 15.725, P < 0.001), high tumor stages (χ2 = 25.416, P < 0.001), tumor sizes >5 cm (χ2 = 8.213, P = 0.005), ipsilateral hydronephrosis (χ2 = 4.624, P = 0.033), and concomitant carcinoma in situ (CIS) (χ2 = 9.517, P = 0.003). A high pretreatment NLR (hazard ratio [HR] = 1.820, P = 0.001), main tumor diameter >5 cm (HR = 1.789, P = 0.009), lymph node metastasis (HR = 1.863, P = 0.024), and high tumor stage (HR = 1.745, P < 0.001) independently predicted poor CSS after surgery, while only concomitant carcinoma in situ (CIS) (HR = 2.164, P = 0.034), ureteroscopy before surgery (HR = 1.701, P = 0.015), and high tumor grade (HR = 1.645, P = 0.018) were independent predictors of IVRFS after RNU.Conclusions:The pretreatment NLR was related to some adverse clinicopathological features and was an independent predictor of CSS, although not IVRFS, in Chinese UTUC patients.

show abstract

Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population1These authors contribute equally.

Cited by 22 publications

References 28 publications

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients

A Case of Synchronous Bilateral Upper Urinary System Urothelial Carcinoma

Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma

Contact Info

Product

Resources

About